Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer/Warner-Lambert

This article was originally published in The Tan Sheet

Executive Summary

Worldwide consumer health care sales dropped 4% to $599 mil. for the third quarter ended Sept. 30 "mainly due to the impact of foreign exchange and the divestiture of the Rid product line" to Bayer, firm announces Oct. 24. Segment revenues in the U.S. also fall 4% from $441 mil. to $425 mil. Losses partially were offset by "strong" sales of Benadryl cold/allergy line, Listerine and Visine. Consolidated revenue of the combined company increased 7% to $7.2 bil., while net income jumped 23% to $1.36 bil. Excluding certain items and merger costs, net income rose 30% to $1.71 bil. Pfizer now anticipates $400 mil. in merger-related savings in 2000, double its previous estimate
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS091831

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel